Pilot study of Phenotype of Antisense-Oligonucleotide-(ASO)-knockdown of Cerebral-Dopamine-Neurotrophic-Factor (CDNF) as Parkinson Disease model : implications for PD and related Dementia Therapeutics
Objective: Our objective is twofold: 1)to examine whether CDNF-ASO paradigm can induce a unique phenotype mimicking PD/PDD/LBW in the rodent species; 2) to evaluate whether…CHAPERONIC PROPENSITIES OF AFRICAN WALNUT AS A THERAPEUTIC TARGET IN MANGANESE-INDUCED PARKINSON-LIKE NEUROPATHOLOGY IN WISTAR RATS
Objective: Herein, the chaperonic propensities of ethanolic extract of African walnut (WNE) in Manganese-induced Parkinson-like neuropathology in the prefrontal cortex and hippocampus was investigated. Background:…Inhibition of GluN2D-containing NMDA receptors alleviates the loss of dopaminergic neurons and behavioral deficits in 6-OHDA-induced model of Parkinson’s disease
Objective: The aim of this study is to explore whether the inhibition of GluN2D-containing NMDA receptors (NMDAR2D) can delay the pathological manifestations of Parkinson's disease…PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results
Objective: Evaluate efficacy and safety of prasinezumab following 52 weeks of treatment in participants with early Parkinson’s disease (PD). Background: Prasinezumab is a humanized monoclonal…Clinical research of serum uric acid levels in Parkinson’s disease
Objective: To analyzed the variation of uric acid (UA) traits in different Hoehn-Yahr staging in Parkinson's disease (PD). Background: PD is a common neurodegenerative disease.…Anti-parkinson effect of natural L-DOPA containing drug Mucuna pruriens against the rotenone induced rat model of Parkinson’s disease
Objective: The nanoherbaceutical formulation comprising natural L-DOPA from Mucuna pruriens against rotenone caused Parkinson's disease in rats to be prepared and evaluated. Background: Parkinson's disease…Effects of a next-generation neurotrophic compound in a toxin model of Parkinson’s disease
Objective: Investigate the effects of a peripherally administered novel neurotrophic compound, CMx01a, in 6-hydroxydopamine rat model of Parkinson’s disease. Background: Neurotrophic factors are promising drug…Creating National Competencies in Physical Activity for Exercise Professionals Working with People with Parkinson’s Disease
Objective: On March 5-6th 2020, the Parkinson’s Foundation is convening a meeting to assemble thought leaders in physical activity and education for Parkinson’s disease. Our…Thiazolidinedione use is associated with reduced risk of Parkinson’s disease in patients with diabetes
Objective: This meta-analysis is aimed to explore the association between thiazolidinedione (TZD) use and Parkinson’s disease (PD) risk. Background: Recent epidemiological studies found protective effects of TZD class of drugs in…Reduced Striatal VMAT2 in REM Sleep Behavior Disorder: A Gateway to Preclinical Parkinson’s Disease
Objective: To determine the degree of striatal degeneration that occurs in subjects with REM Sleep Behavior Disorder (RBD) and assess whether this is an appropriate…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 13
- Next Page »